齐多夫定不耐受或治疗失败时的治疗选择。
Treatment options in zidovudine intolerance or failure.
作者信息
Abrams D I
机构信息
Terry Beirn Community Programs for Clinical Research on AIDS, University of California, San Francisco.
出版信息
AIDS. 1994 Sep;8 Suppl 3:S3-7. doi: 10.1097/00002030-199409001-00002.
AIM
To compare the efficacy and safety of didanosine and zalcitabine in patients who could not tolerate zidovudine or who had failed to respond adequately.
PATIENTS AND METHODS
A multicentre, randomly allocated, open-label clinical trial was set up with 230 patients treated with didanosine and 237 treated with zalcitabine. All had previously been treated unsuccessfully with zidovudine. The patients were followed for at least 1 year, with an average of 16 months.
RESULTS
Disease progression or death occurred in 157 patients taking didanosine and 152 taking zalcitabine. There appeared to be a slight trend in favour of survival in the latter group.
CONCLUSIONS
There is an urgent need for more effective and better tolerated antiretroviral agents in the treatment of HIV infection. Zalcitabine is at least as effective as didanosine and may provide a survival advantage in patients treated unsuccessfully with zidovudine.
目的
比较去羟肌苷和扎西他滨在不能耐受齐多夫定或对齐多夫定反应不佳的患者中的疗效和安全性。
患者与方法
开展了一项多中心、随机分配、开放标签的临床试验，230例患者接受去羟肌苷治疗，237例患者接受扎西他滨治疗。所有患者此前接受齐多夫定治疗均未成功。对患者进行了至少1年的随访，平均随访时间为16个月。
结果
服用去羟肌苷的157例患者和服用扎西他滨的152例患者出现疾病进展或死亡。后一组似乎有略微有利于生存的趋势。
结论
在治疗HIV感染方面，迫切需要更有效且耐受性更好的抗逆转录病毒药物。扎西他滨至少与去羟肌苷一样有效，并且可能为接受齐多夫定治疗未成功的患者提供生存优势。
Zotero 插件